May 19, 2013


Mario Eisenberger, M.D.

R. Dale Hughes Professor of Oncology and Urology
Johns Hopkins Medical Institutions


Email:marioe@welchlink.welch.jhu.edu

PUBLICATIONS

JOURNAL ARTICLES

Free Access to abstracts at PubMed

  1. Geller M, Eisenberger MA. Consideracoes gerais sobre cardiopatias congenitas. A Folha Medica 62(4): 419-432, 1971.

  2. Tejada F, Eisenberger M, Broder L, Cohen M, and Simon R. 5-Fluorouracil versus CCNU in the treatment of metastatic prostatic cancer. Cancer Treat Reports 6:1589-1590, 1977.

  3. Denefrio J, Kaplan R, Eisenberger M, and Lessner HE. Phase II study of cyclophosphamide and cytarabine in the treatment of adenocarcinoma of the colon and rectum. Cancer Treat Reports 65:163-164, 1980.

  4. Eisenberger M. The role of chemotherapy in the treatment of head and neck cancer. Miami Medicine 1:23, 1980.

  5. Eisenberger M, Denefrio J, Silverman M, and Lessner H. Combination chemotherapy with bleomycin and hydroxyurea in the treatment of advanced head and neck cancer. Cancer Treat Rep 66:1438-1440, 1982.

  6. Warner B, Worgul T, Drago, J, Demers L, Dufau M, Hay D, Santen R, and Members of the Abbot Study Group. Effects of very high dose D-leucine 6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer. Journal Clinical Invest 71:1842-1853, 1983. (Major Input in Patient Accrual and Active Participant in Study).

  7. Eisenberger M. Combination chemotherapy with bleomycin and hydroxyurea in the treatment of advanced head and neck cancer. O.R.I. Digest 4-5, 1983.

  8. Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. NEJM 311:1281-1286, 1984. (Participated in the preparation of the manuscript and accrued over 10% of the patients reported).

  9. Eisenberger M, Simon R, O'Dwyer P, Wittes R, and Friedman M. A re-evaluation of non-hormonal cytotoxic chemotherapy in the treatment of prostatic cancer. J Clin Oncol 3:827-841, 1985.

  10. Eisenberger M. Supporting evidence for an effective treatment program for salivary gland tumors. Cancer Treat Reports 69:319-321, 1985.

  11. Krasnow W, Patterson D, Fishman B, Eisenberger M, Johnston-Early A, Citron M, and Cohen M. Local toxicity from intravenous Baker's Antifol. Cancer Treat Reports 65:735-736, 1985.

  12. O'Dwyer P, Leyland-Jones B, Alonso M, Eisenberger M, and Hoth D. Dichloromethotrexate - A critical reassessment. J Clin Oncol 3:1148-1153, 1985.

  13. Ellenberg S, and Eisenberger M. An efficient design for phase II studies of combination chemotherapies. Cancer Treat Reports 1147-1152, 1985.

  14. Smith J (for Leuprolide Study Group). Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate. Urology 25:106-114, 1985 (Member of the Leuprolide Study Group).

  15. Eisenberger M, O’Dwyer P, Friedman M. Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma. J Clin Onc 4:414-424, 1986.

  16. Eisenberger M, Hornedo J, Silva J, Donehower R, Spaulding M, and Van Echo D. Carboplatin (NSC-241-240): An active platinum analog for the treatment of squamous cell carcinoma of the head and neck. J Clin Oncol 4:1506-1509, 1986.

  17. Krasnow S, Green M, Perry D,Eisenberger M, Johnson-Early A, Muggia F, and Cohen M. Phase II trial of Baker's antifol in patients with recurrent or inoperable head and neck cancer. Cancer Treat Rep 70:1039-1040, 1986.

  18. Vogel CL, Gorowski E, Davila E, Eisenberger M, Kosinski J, Agonwal R, and Savaroj N. Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169 780) infusion in patients with solid tumors. Investigational New Drugs 5:187-198, 1987.

  19. Tchekmedyian N, Kaplan R, Eisenberger M, Abrams J, and Van Echo D. Phase II study of Nmethylformamide (NMF) in patients with advanced colorectal cancer. Cancer Treat Rep 71:541-542, 1987.

  20. Eisenberger M, Kennedy P, and Abrams J. Cytotoxic chemotherapy for disseminated prostatic cancer. Oncology 4:4:59-69, 1987.

  21. Belani C, Eisenberger M, Van Echo D, Hiponia D, and Aisner J. A phase II study of caracemide in advanced or recurrent non-small cell lung cancer. Cancer Treat Rep 71:1099-1100, 1987.

  22. Conley B, Hornedo J, Abrams J,Eisenberger M, Hiponia D, Aisner J, and Van Echo D. A phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer. 71:861-862, 1987.

  23. Eisenberger M, Bezerdjian L, and Kalash S. A Critical evaluation of non-hormonal cytotoxic chemotherapy for advanced prostatic cancer. Urological Clinics of North America. Donnoghue J (ed) 14(4): 695-706, 1987.

  24. Eisenberger M. Controversies involving the systemic treatment for metastatic prostatic cancer. Rev Bras Cancerol 33:39-49, 1987.

  25. Chodak GW, Eisenberger MA, Scardino PT, Torit FM. Detecting prostate cancer early. Patient Care 21(7): 69-73, 1987.

  26. Chodak GW, Eisenberger MA, Scardino PT, Torti FM. Current management for prostate cancer. Patient Care 21(7): 74-93, 1987.




  27. Chodak G, Eisenberger M, Scardino P, and Torti F. Diagnosis and treatment of prostatic cancer. Patient Care 25:69-93, 1987.


  28. Eisenberger MA, Bezerdjian L, Kalash S. A Critical Assessment of the Role of Chemotherapy for Endocrine-Resistant Prostatic Carcinoma. Urol Clin North Am. 1987 Nov;14(4):695-706.


  29. Eisenberger M, and Abrams J. Gonadotropin hormone releasing hormone for the treatment of prostatic cancer. Drugs of Today, J.R. Rpis (ed), Barcelona, Spain, 24:241-248, 1988.

  30. Eisenberger M, Jacobs M, Drake K, Bajaj K, Kennedy P, Elias G, and Gray W. Simultaneous treatment with carboplatin (CBDCA) and conventional radiotherapy for unresectable loco-regional squamous cell carcinoma of the head and neck, Phase I-II study. Head and Neck Oncology Research 1:431-436, 1988.


  31. Eisenberger M, and Abrams JS. Chemotherapy for prostatic carcinoma. Semin Urology VI (4): 303-310, 1988.


  32. Eisenberger M, Bezirdjian L, and Kalash S. A critical assessment of the role of chemotherapy for endocrine resistant prostatic carcinoma. American Urological Update Series, Lesson 28, Volume VII: 218-224, 1988.


  33. Eisenberger M, Ellenberg S, Leyland-Jones B, and Friedman M. The application of a two-stage design clinical trials in patients with recurrent head and neck cancer. Med Ped Oncol 16:162-168, 1988.


  34. Belani C, Eisenberger M, and Gray W. Preliminary experience with combination chemotherapy in the treatment of advanced neoplasms of the salivary glands. Med Ped Oncology 16:197-202, 1988.


  35. Eisenberger M. Chemotherapy for prostate carcinoma-. In: NIH Consensus Development Conference on the Treatment of Prostate Cancer, NCI monograph 7:151-163, 1988.


  36. Eisenberger M, Jacobs M, Sinibaldi V, and Gray W. Simultaneous treatment with CBDCA (NSC 241-240) and radiotherapy in advanced unresectable squamous cell carcinomas of the head and neck. Cancer Treat Rev 15(B):3-7, 1988.


  37. Nanus D, Kelsen D, Lipperman R, and Eisenberger M. Phase-II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity. Investigational New Drugs 6:239-241, 1988.


  38. Crawford E, McLeod D, Dorr A, Spaulding J, Benson R, Eisenberger M, Blumenstein B. A Comparison of leuprolide with flutamide and leuprolide in untreated stage D2 prostate cancer. Endocrinology 2:63, 1988.


  39. Eisenberger M, Van Echo D, Aisner J. Carboplatin the experience in head and neck cancer. Seminars in Oncology 16(21): 5:34-41, 1989.


  40. Jacobs M, Eisenberger M, Oh MC, Sinibaldi V, Gray W, Elias G, and Salazar O. Carboplatin and radiation for stage IV carcinoma of the head and neck: A phase I-II study. Int J Radiation Oncology Biol Phys 17: 361-363, 1989.


  41. Crawford E, Eisenberger M, Benson R, McLeod D, Dorr A, Spaulding S, Blumenstein B, Davis M, and Goodman P. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. NEJM 321:419-424, 1989.


  42. Eisenberger M, Krasnow S, Ellenberg S, Sinibaldi V, Silva H, Abrams J, Van Echo D, and Aisner J. A comparison of carboplatin and methotrexate versus methotrexate alone in recurrent head and neck cancer. J Clin Oncol 7:1341-1345, 1989.


  43. Abrams J, Tait N, Silva H, Eisenberger M, Van Echo D, Oliver I, and Aisner J. Phase II trial of N-methylformamide in advanced renal cancer. Am J Clin Oncol (CCT) 12:41-42, 1989.


  44. Belani C, Egorin M, Abrams J, Hiponia D, Eisenberger M, Aisner J, Van Echo D. A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide. J Clin Oncol 7:1896-1902, 1989.


  45. Eisenberger M, Krasnow S, Ellenberg S, Silva H, Abrams J, Sinibaldi V, Van Echo D, Aisner J. A Comparison of Carboplatin Plus Methotrexate Versus Methotrexate Alone in Patients With Recurrent and Metastatic Head and Neck Cancer. J Clin Oncol 8:1341-1345, 1989.


  46. Eisenberger MA. Chemotherapy for endocrine resistant cancer of the prostate. Prog Clin Biol Res. 1990;359:155-64.


  47. Ginn D, Kelsen D, Eisenberger M, Heelan R, and Magill G. Phase II trial of carboplatin and vinblastine in adenocarcinoma of the stomach. Investigational New Drugs 8:321-324, 1990.


  48. Eisenberger M. The management of endocrine resistant prostate cancer. World J Urol 8:40-46, 1990.


  49. Scher H, Smart Curley J, Geller N, and Eisenberger M. Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J Clin Oncol 1830-1838, 1990.


  50. Abrams J, Rayner A, Wiernik P, Parkinson D, Eisenberger M, and Hawkins M. High dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell cancer. J Natl Cancer Inst. 82:1202-1206, 1990.


  51. Crawford E, Blumenstein B, Goodman P, Davis M, Eisenberger M, McLeod D, Spaulding J, Benson R, and Dorr A. Leuprolide with and without flutamide in advanced prostate cancer. Cancer 66:1039-1044, 1990.


  52. Von Hoff D, Blumenstein B, Pollock T, Crawford E, Eisenberger M et al. Phase II study of methyl-glioxal bis-guanylhydrazone (MGBG) in patients with advanced bladder cancer. European Journal of Cancer 26: 848-849, 1990.


  53. Lovett D, Kelsen D, Eisenberger M, and Houston C. A Phase II trial of carboplatin and vinblastine in the treatment of advanced squamous cell carcinoma of the esophagus. Cancer 67:354-356, 1991.


  54. Crawford E, Eisenberger M, McLeod D, et al. A comparison of leuprolide - with and without flutamide - in previously untreated patients with disseminated prostate carcinoma. Exerpta Medica N. 477, 1991.


  55. Kruter F, Eisenberger M, Sinibaldi V, Jacobs M, and Gray W. Continuous infusion IV 6-thioguanine for patients with recurrent and metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 10: 89-91, 1991.


  56. McLeod D, Crawford E.D, Blumenstein B, Eisenberger M, Dorr F.A. Controversies in the treatment of metastatic prostate cancer. Cancer 70:324-328, 1991.


  57. Benson RC, Jr, Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Dorr FA. National Cancer Institute study of luteinizing hormone-releasing hormone plus flutamide versus luteinizing hormone-releasing hormone plus placebo. Semin Oncol. 1991 Oct;18(5 Suppl 6):9-12.


  58. Eisenberger MA, Fontana JA. Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer: compelling reasons for testing in patients with hormone-refractory breast cancer. J Natl Cancer Inst. 1992 Jan 1;84(1):3-5.


  59. Eisenberger M. Chemotherapy for carcinomas of the penis and urethra. Urological Clinics of North America 19:333-338, 1992.


  60. Eisenberger M, and Jacobs M. Simultaneous treatment with single agent chemotherapy and radiation therapy for locally advanced cancer of the head and neck. Seminars in Oncology 19 (Suppl 11):41-46, 1992.


  61. Gregory L, Eisenberger M, and Sinibaldi V. Analytical interference associated with suramin administration. Clinical Chemistry 38: 2552-2553, 1992.


  62. Eisenberger M, Reyno L, Jodrell D, Sinibaldi V, Tkaczuk K, Sridhara R, Zuhowski E, Louis M, Jordon SC, and Egorin MJ. Suramin, An active drug for prostate cancer: Interim observation in a phase I trial. JNCI 85:611-621, 1993.


  63. McLeod D, Benson R, Eisenberger M, Crawford E, Blumenstein B, Spicer D, and Spaulding J. The use of flutamide in hormone-refractory metastatic prostate cancer. Cancer (Suppl.) 75:3870-3873, 1993.


  64. Marshall M, Wolf M, Crawford E, Taylor S, Blumenstein B, Flanigan R, Meyers F, Hynes H, Barlogie B, and Eisenberger M. Phase-II trial of echinomycin for the treatment of advanced renal cell carcinoma. Investigational new Drugs 11:207-209, 1993.


  65. Marshall EM, Blumenstein B, Crawford E, Thompson I, Craig J, Eisenberger M, and Ahman F. Phase II trial of Amonafide for the treatment of hormonally refractory carcinomas of the prostate: A Southwest Oncology Group Study. Am J Clin Oncol 17:514-515, 1994.


  66. Jodrell D, Reyno L, Sridhara R. Eisenberger MA, Tkaczuk K, Zuhowski E, Sinibaldi V, Novak M, and Egorin M. Suramin: Development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. J. Clin Oncol 12:166, 1994.


  67. Hussain M, Wolf M, Marshall E, Crawford E, and Eisenberger M. Effects of continued androgen deprivation therapy and other prognostic factors on response and survival in phase-II chemotherapy trials for hormone-refractory prostate cancer: A Southwest Oncology Group Report, J Clin Oncol 12:1868-1875, Sept.1994.


  68. Eisenberger M and Reyno L. New Drugs: Suramin. Cancer Treat Rev: 259-273, 1994.


  69. Eisenberger M, Crawford E, Wolf M, Blumenstein B, McLeod D, Benson R, Dorr F, Benson M, and Spaulding J. Prognostic factors in stage D2 prostate cancer; important implications for future trials: Results of a cooperative intergroup study (INT. 0036). Seminars in Oncology 21:613-619, 1994.


  70. Eisenberger MA, Reyno LM. Suramin. Cancer Treat Rev. 1994 July;20(3):259-73.


  71. De Antoni E, Crawford E, Stone N, Blum D, Berger R, Eisenberger M, Gambert S, and Staggers F. Prostate Cancer Awareness Week, 1992: A summary of key findings. Clin Invest Med 16:448-457, 1994.


  72. Marshall M, Blumenstein B, Crawford E, Win Q, Miller T, Meyers F, Wolfe M, Eisenberger M, and Einstein A. A phase II study of CHIP for the treatment of hormonally refractory carcinoma of the prostate: A Southwest Oncology Group Study. American Journal of Clin Oncol 18:400-402, 1995.


  73. Jacobs M, Suntharalingam M, Eisenberger M, Sinibaldi V, and Salazar O. Combined carboplatin + bleomycin and conventional radiotherapy for advanced head and neck cancer. Amer J Clin Onc 18:1, 52-55, 1995.


  74. Crawford E, Hussain M, DeAntoni E, Thompson I, Eisenberger M, Blumenstein B, and Coltman C. Southwest Oncology Group Strategies in Prostatic Carcinoma: Seminars in Surgical Oncology. 11:60-64, 1995.


  75. Williamson S, Wolf M, Eisenberger M, O'Rourke M, Brannon W, and Crawford ED. Phase II evaluation of didemnin b in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group Study. Invest New Drugs 13:167-170, 1995.


  76. Twillie D, Eisenberger M, Carducci M, Hseih W-S, Kim W, and Simons J. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45:542-549, 1995.


  77. Sridhara R, Eisenberger M, Sinibaldi V, Reyno L, and Egorin M. Evaluation of prostate-specific antigen as a surrogate marker for prostate cancer to suramin therapy. J Clin Oncol 13:2944-2953, 1995.


  78. Williamson SK, Wolf MK, Eisenberger MA, O'Rourke M, Brannon W, Crawford ED. Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study. Invest New Drugs. 1995;13(2):167-70.


  79. Eisenberger MA, Sinibaldi V, Reyno L, Sridhara R, Jodrell DI, Zuhowski E, Tkaczuk K, Lowitt M, Hemady RK, Jacobs SC, Van Echo D, and Egorin M. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 13:2174-2186, 1995.


  80. Eisenberger MA, Sinibaldi V, Reyno L. Suramin. Cancer Pract. 1995 May-Jun;3(3):187-9.


  81. Reyno L, Egorin M, Eisenberger M, Sinibaldi V, Zuhowski E, and Sridhara R. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 13:2187-2195, 1995.


  82. Nelson J, Hedican S, George D, Reddi, A.H., Piantadosi S, Eisenberger M, and Simons J. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med 1:944-949, 1995.


  83. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. The Lancet 346:265-269, 1995.


  84. Lowitt M, Eisenberger M, Sina B, and Kao G. Cutaneous eruptions from suramin: a clinical and histopathologic study of 60 patients. Arch Dermatol 131:1147-1153, 1995.


  85. Eisenberger M, Reyno L, Sinibaldi V, Sridhara R, Carducci M, and Egorin M. The experience with suramin in advanced prostate cancer. Cancer 75:1927-1934, 1995.


  86. Williamson S, Wolf M, Eisenberger M, O'Rourke M, Brannon W, and Crawford E. Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group Study. Amer J of Clin Onc (CCT) 19(4):368-370, 1996.


  87. Eisenberger MA, Nelson WG. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution! J Natl Cancer Inst. 1996 Jun 19;88(12):779-81.


  88. Eisenberger M, Sinibaldi V, Reyno L, Sridhara R, Jacobs S, and Egorin M. Active and safe schedule developed for outpatient use of suramin. AUA Today 9:1, 1996.


  89. Hemady R, Sinibaldi V, and Eisenberger M. Ocular symptoms and signs associated with suramin sodium treatment for metastatic cancer of the prostate. Amer Jour Opthalmology 121:291-296, 1996.


  90. Crawford E, DeAntoni E, Etzioni R, Schaefer V, Olson R, Ross C, and Eisenberger M. Serum prostate-specific antigen and digital rectal examination for the early detection of prostate cancer in a national community-based program. Urology 14:863-869, 1996.


  91. Chaudhry V, Eisenberger M, Sinibaldi V, Sheikh K, Griffin J, and Cornblath D. A prospective study of suramin-induced peripheral neuropathy. Brain 119:2039-2052, 1996.


  92. Eisenberger M and Nelson W. How much can we rely on psa as an endpoint for evaluation of clinical trials? A word of caution! JNCI 88(12):779-781, 1996.


  93. Hussain M, Blumenstein B, Eisenberger M, and Crawford E.D. Southwest Oncology Group Studies in Hormone Refractory Prostate Cancer. Sem in Onc 23(14):24-27, 1996.


  94. Carducci M, DeWeese T, Nelson W, Simons J, Sinibaldi V, and Eisenberger M. Prostate cancer treatment strategies based on tumor-specific biological principles: the Johns Hopkins approach. Sem in Onc 23(14):56-62, 1996.


  95. Newling D, Fossa S, Andersson L, Per-Anders A, Yoshio A, Eisenberger M, Khoury S, Kozlowski J, Kelly K, Scher H, Hartley-Asp B. Assessment of hormone refractory prostate cancer. Urology 49(4a):46-53, Suppl April 1997.


  96. Eisenberger M, Sinibaldi V, Reyno L, Sridhara R, Jodrell D, Zuhowski E, Tkaczuk K, Lowitt M, Hemady R, Stephen J, VanEcho D and Egorin M. Phase I and Clinical Evaluation of a Pharmacologically Guided Regimen of Suramin in Patients With Hormone-Refractory Prostate Cancer. Classic Papers and Current Comments, Vol 2 (No 2) 1997:345-357.


  97. Eisenberger M. Submitted to Oncology by invitation - Commentary on an article entitled A Management of progressive metastatic prostate cancer.@ Oncology 11(10): 1560-1561, 1997.


  98. Sridhara R, Eisenberger M, Sinibaldi V, Reyno L, Egorin M. Evaluation of Biomarkers of Survival response in Hormone-Refractory Prostate Cancer Patients Treated with Suramin. Cancer Epidemiology, Biomarkers, Vol 7, 631-634, July 1998.


  99. Moinpour C, Savage M, Troxel A, Lovato L, EisenbergerM, Veith R, Higgins B, Skeel R, Yee M, Blumenstein B, Crawford D, Meyskens F. Quality of Life In Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial. J Natl Cancer Inst 90:1537-44, 1998.


  100. Eisenberger M, Blumenstein B, Crawford E, McLeod D, Loehrer p, Wilding G, Sears K, Culkin D, Thompson I, Bueshen A, Lowe B. A Randomized and Double-Blind Comparison of Bilateral Orchiectomy with or without Flutamide for the Treatment of Patients with Stage D2 Prostate Cancer: Results of NCI Intergroup 0105. N ENG J Med 339:1036-42, 1998.


  101. Sridhara R, Eisenberger M, Reyno LM, Jodrell DI, Sinibaldi V, Zuhowski EG, Egorin MJ. Comparison of Iterative-Two Stage and Bootstrap Sampling Approaches in the Development of a Population Pharmacokinetic Model. International Federation of Automatic Control pp 141-145, March 1998.


  102. Eisenberger, MA. Modulation of Growth Factors Action as a Therapeutic Objective in Prostate Cancer. Acta Urologica Italicay Vol 12 (1Suppl):181-182, 1998.


  103. Pound C, Partin A, Eisenberger M, Chan D, Pearson J, Walsh P. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1591-1597, 1999.


  104. Eisenberger C, Walsh P, Eisenberger M, Chow Nan-Haw, Partin A, Mostwin J, Marshall F, Epstein J and Schoenberg M. Incidental Non-Hodgkin’s Lymphoma in Patients with Localized Prostate Cancer. Urology 53:175-179, 1999.


  105. Laufer M, Carducci M, Blumenstein B, Eisenberger M. Combined Androgen Blockade (CAB) For The Treatment Of Patients With Metastatic Prostatic Cancer: Summary Of 15 Years Of Clinical Research. AUA Update Series Lesson 29: Volume XVIII, 1999.


  106. Jodrell D, Reyno L, Sridhara R. Eisenberger M, Tkaczuk K, Zuhowski E, Sinibaldi V, Novak M, and Egorin M. Suramin: Development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. Classical Papers and Current Comments, Vol 4, No 1:pp 264-273, 1999.


  107. Laufer M, Sinibaldi VJ, Carducci MA, and Eisenberger MA. Rapid disease progression after the administration of bicalutamide in patients with metastatic Prostate cancer. Urology, Vol 54, No. 4:745, October 1999.


  108. Short Course of Estramustine Phosphate and Docetaxel (Taxotere) in the Treatment of Hormone-Refractory Prostate Cancer - Seminars in Oncology, Vol 26, No 5, Suppl 17: pp 45-48, October 1999.


  109. Bubley G, Carducci M, Dahut W, Dawson N, Deliani D, Eisenberger M, Figg W, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak D, Reed E, Roth B, Santor O, Scher H, Simons J, Sinibaldi V, Small E, Smith M, Trump D, Vollmer R, Wilding G. Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the PSA Working Group. J Clin Oncol, Vol 17, No 11:3461-3467, 1999.


  110. Eisenberger MA and Walsh PC. Early androgen deprivation for prostate cancer? N Eng J Med, 341:1837, 1999.


  111. PCTCG. Maximum Androgen Blockage In Advanced Prostate Cancer: An Overview of the Randomized Trials - Prostate Cancer Trialists’ A Collaborative Group* - Lancet: 355:1491-98, 2000.


  112. Laufer M, Pound C, Carducci M and Eisenberger M. Management Of Patients With Rising Prostate-Specific Antigen After Radical Prostatectomy. Urology 55:309-315, 2000.


  113. Sinibaldi V, Eisenberger M. Preliminary Evaluation of Docetaxel Plus 1-Day Estramustine In The Treatment Of Prostate Cancer. Advances In Prostate Cancer, Vol 4, No 1: pp 8-10, March 2000.


  114. Eisenberger MA. Editorial Comment. Urology, Vol. 55, No. 3:395-396, March 2000


    .
  115. Small E, Meyer M, Marshall E, Reyno L, Meyers F, Natalie R, Lenehan P, Chen L, Slichenmyer W, and Eisenberger M. Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone To Placebo Plus Hydrocortisone. J Clin Oncol Vol 18:1440-1450, 2000.


  116. Hussain M, Fisher E, Petrylak D, Wood D, Small E, Eisenberger M, and Crawford E. Androgen Deprivation and 4-Courses Fixed Schedule Suramin In Patients With Newly Diagnosed Metastatic Prostate Cancer: A Southwest Oncology Group Study. J Clin Oncol Vol 18:1043-1049, 2000.


  117. Sinibaldi V and Eisenberger M. Systemic Treatment of Hormone-Refractory Prostate Cancer, Revista da Sociedade Brasileira de Oncologia. SBOC Revista, Vol 2: 73-87, 2000.


  118. Laufer M, Denmeade S, Sinibaldi V, Carudcci M, Eisenberger M. Complete Androgen Blockade For Prostate Cancer: What Went Wrong?! J Urol Vol 164:3-9, 2000.


  119. Laufer M, Sinibaldi V and Eisenberger M. Treatment of Advanced Prostate Cancer. Clinical Oncology: Update Edited by: Martin D. Abeloff, James C. Armitage, Allen S. Lichter and John E. Neiderhuber. Vol 3, No 1:1-12, June 2000.


  120. Wang ZP, Eisenberger MA, Carducci MA, Partin AW, Scher HI, and Ts’o PO. Identification and characterization of circulating prostate carcinoma cells. Cancer 15; 88(12): 2787-2795, June 2000.


  121. Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, Donnelly J, Eisenberger MA, Escalante C, Hinds P, Jacobsen PB, Kaldor P, Knight SJ, Peterman A, Piper BF, Rugo H, Sabbatini P, and Stahl C. NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Hunting). 14(11A):151-161, November 2000.


  122. Laufer M, Schoenberg M and Eisenberger M. Paclitaxel-Induced Stomal Neuropathy: A Unique Cause of Pain in Patient With Ileal Conduit. Urology 56(6):1056, Dec 20, 2000.


  123. Pienta K, Fisher E, Eisenberger M, Mills G, Goodwin J, Jones J, Dakhil S, Crawford E and Hussain M. A Phase II Trial of Estramustine and Etoposide In Hormone Refractory Prostate Cancer: A Southwest Oncology Group Trial (SWOG-9407) - The Prostate Vol 46, No 4:257-261, 2001.


  124. Thompson I, Tangen C, Tolcher A, Crawford D and Eisenberger M. African American Ethnic Background Is Associated With Significant Reduction In Survival In Men With Metastatic Prostate Cancer: Results Of A Randomized, Prospective Trial (SWOG-8894) JNCI Vol 93, No, 3, 2001.


  125. Roberts W, Carducci M, Han M, Epstein J, Eisenberger M, Walsh P and Partin A. Contemporary Identification of Patients at High-Risk of Early Prostate Cancer Recurrence after Radical Retropubic Prostatectomy. Urology 57:1033-1037, 2001.


  126. Small E, McMillian A, Meyer M, Chen L, Slichenmyer W, Lenehan P and Eisenberger M. Serum Prostate-Specific Antigen Decline as a Marker of Clinical Outcome in Hormone-Refractory Prostate Cancer Patients: Associated With Progression-Free Survival, Pain End Points, and Survival. J Clin Oncol Vol 19:1304-1311, 2001.


  127. Schroder L, Lew D, Flanigan R, Eisenberger M, Seay T, Hammond N, Needles B and Crawford D. Phase II Evaluation Of Suramin In Advanced Renal Cell Carcinoma – A Southwest Oncology Group Study. Urologic Oncol Vol 6, 2001:145-148.


  128. Kucuk O, Fisher E, Moinpour C, Coleman D, Hussain M, Sartor O, Chatta G, Lowe B, Eisenberger M. and Crawford, D. Phase II Trial of Bicalutamide (casodex) in Patients with Advanced Prostate Cancer in Whom Conventional Hormonal Therapy: A Southwest Oncology Group Study (SWOG 9235)-Urology 58:2001: 53-58.


  129. Walsh PC, DeWeese TL, Eisenberger MA. A Structured Debate. Immediate Versus Deferred Androgen Suppression In Prostate Cancer: Evidence For Deferred Treatment. J. Urol Vol 166, 2001:508-516.


  130. Eisenberger MA. Recent Developments in Chemotherapy for Bladder Cancer Oncology. Vol 15, No. 6:779-780, June 2001.


  131. Walsh PC, DeWeese TL and Eisenberger MA. A Structured Debate: Immediate Versus Deferred Androgen Suppression in Prostate Cancer – Evidence for Deferred Treatment. Journal of Urology Vol. 166, 508-516, August 2001.


  132. Carducci M, Gilbert J, Bowling K, Noe D, Eisenberger M, Sinibaldi V, Zabelina Y, Chen T, Grochow L and Donehower R. A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on a 120-h infusion schedule. Clin Cancer Res 2001; 7:3047-3055.


  133. Pienta KJ, Fisher EI, Eisenberger MA, Milss GM, Goodwin JW, Jones JA, Dakhil SR, Crawford ED, Hussain MH. A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407) Prostate. 2001 March 1;46(4):257-61.


  134. Eisenberger MA. Surgical Adjuvant Chemotherapy in High Risk Patients With Prostate Cancer: Are We Ready For A Prime Time? Advances in Prostate Cancer, March 2002; Vol. 6, No. 2:3-4.


  135. Sinibaldi V, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, and Eisenberger MA. Phase II Evaluation of Docetaxel plus One-Day Oral Estramustine Phosphate in the Treatment of Patients with Androgen Independent Prostate Carcinoma. Cancer 2002 Mar 1;94(5):1457-65.


  136. Lassiter LK and Eisenberger MA. The Dilemma of Patients with a Rising PSA Level After Definitive Local Therapy for Prostate Cancer. Seminars in Urologic Oncology, May 2002; Vol. 20, No. 2:146-154.


  137. Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinabaldi V, Donehower R, Leahy TL, Carr RA, Isaacson JD, Janus TJ, Andre A, Hosmane BS, and Padley RJ. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J. Clin. Oncol. April 15 2002, 20 (8):2171-2180.


  138. Eisenberger MA. Therapeutic considerations for patients with high-risk, nonmetastatic, prostate cancer. Semin. Urol. Oncol. August 2002, Vol 20 (3 Suppl 1):19-23.


  139. Lieb J, Basaria S, Tang A, DeWeese T, Carducci M, Eisenberger M and Dobs A. Long Term Effects Of Androgen Deprivation Therapy In Prostate Cancer Patients. Clinical Endocrinology 2002; 56:779-786.


  140. Sokoll LJ, Bruzek DJ, Dua R, Dunn W, Mohr P, Wallerson G, Eisenberger M, Partin AW and Chan DW. Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed. Urology 2002.


  141. Eisenberger, M. Prostate Specific Antigen. New England Journal of Medicine, 346 (9):715, 2002.


  142. Antonarakis ES, Eisenberger MA. Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer? Cancer. 2002 Mar 1;94(5):1457-65.


  143. Eisenberger, M. Hormonal Therapy for Advanced Prostate Cancer. The Johns Hopkins White Paper Bulletins. Prostate Bulletin Winter Issue, 23-32, December 23, 2002.


  144. Lassiter LK, Eisenberger MA. The dilemma of patients with a rising PSA level after definitive local therapy for prostate cancer. Semin Urol Oncol. 2002 May;20(2):146-54.


  145. Sinibaldi V, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M and Eisenberger MA. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 2002 Mar 1;94(5):1457-65.


  146. Laufer M., Ramalingam S, Schoenberg, MP, Haisfield-Wolf ME, Zuhowski EG, Truehart IN, Eisenberger MA, Nativ O, and Egorin MJ. Intravesical Gemcitabine Therapy for Superficial Transitional Cell Carcinoma of the Bladder: A Phase I and Pharmacokinetic Study. J Clin Oncol Vol 21, (4):697-703, 2003.


  147. Eisenberger MA, Laufer M, Vogelzang NJ, Sartor O, Thorton D, Neubauer BL, Sinibaldi V, Lieskovsky G, Carducci MA, Zahurak M, Raghavan D. Phase I and Clinical Pharmacology of a Type I and II, 5 a-Reductase Inhibitor (LY-320236) in Prostate Cancer: Elevation of Estradiol as the Possible Mechanism of Action. Urology 2004 Jan;62(1):114-9.


  148. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Odard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 Oct 7;351(15):1502-12.


  149. Tangen CM, Faulkner JR, Crawford ED, Thompson IM, Hirano D, Eisenberger M, Hussain M. Ten-Year Survival with Metastatic Prostate Cancer. Clin Prost Ca, June 2003.


  150. Eisenberger M. Taxol induced neurotoxicity presenting as stomal pain in a patient with ileal conduit. Urology 2003.


  151. Eisenberger MA. A Multi-Institutional Pilot Study of Adjuvant Docetaxel for Patients with Prostate Cancer at High Risk for Relapse after Radical Prostatectomy. MedReviews, Vol. 5, (Supp. 2):S42-S47, 2003.


  152. Sunkara U, Walczak JR, Summerson L, Rogers T, Eisenberger M, Denmeade S, Pili R, Huff CA, Sinibaldi V, and Carducci MA. A Phase II Trial of Temozolomide and IFN-α in Patients with Advanced Renal Cell Carcinoma. J. of Interferon & Cytokine Research , 24:37-41, 2004.


  153. Scher HI, Eisenberger MA, D’Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff, et al. Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group. J. of Clin. Onc., Vol. 22, (3), pg 537-556, February, 2004.


  154. Rosenbaum E, Partin A, and Eisenberger M. Biochemical Relapse After Primary Treatment for Prostate Cancer: Studies on Natural History and Therapeutic Considerations. JNCCN, Vol. 2 (3); 249-256, May 2004.
  155. D’Amico AV, Eisenberger MA, Partin AW, Pienta KJ. Therapeutic strategies for patients with a rising PSA: A case-based approach. Report to the Nation on Prostate Cancer 2004 (Carroll P, Nelson W Eds), Prostate Cancer Foundation, pp. 85-92. 2004.


  156. Eisenberger MA, Partin AW. Progress toward identifying the aggressive subtype of Postate Cancer Subtype. N Engl J Med 2004; 180-181.


  157. Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, Nicholas DJ, Turesson I, Rosenthal MA and Eisenberger MA, on behalf of the TAX 327 Investigators. Randomized comparison of weekly or three- weekly docetaxel plus prednisone with mitoxantrone plus prednisone for treatment of patients with advanced hormone-refractory prostate cancer. N Engl J Med 2004; 1502-1512.

  158. Scher HI, Eisenberger MA, D’Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, KAntoff P, Pienta KJ, Carducci MA, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, William B, Wilding G, Moul JW, Partin AN, Logothrtis C, Soule HR. Eligibility & Outcomes reporting guidelines for clinical trails for patients in the State of a Rising Prostate-Specific Antigen: Recommendations from the PSA working Group. Sponsored by the American Society of Clinical Oncology. Journal of Clinical Oncology 22:537-556. 2004


  159. Freedland SJ, Humphreys EB, Mangold LA, Partin AW, Eisenberger MA, Walsh PC. Predicting Prostate Cancer Specific Mortality Following Biochemical Recurrence after Radical Prostatectomy. JAMA. 2005;294:433-439.


  160. Bastian P, Palapattu G, Lin X, Yegnasubramanian S, Mangold L, Trock B, Eisenberger MA, Partin A, Nelson W. Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy. American Association for Cancer Research, Vol. 11(11); 4037-4043, 2005.


  161. Rosenbaum E, Zahurak M, Sinibaldi V, Carducci MA, Pili R, Laufer M, DeWeese TL, Eisenberger, MA. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: A prospective randomized, double blind, phase I/II trial. Clinical Cancer Research, Vol. 11(12); 4437-4443, 2005.


  162. Berry W, Eisenberger M. Achieving Treatment Goals for Hormone-Refractory Prostate Cancer. The Oncologist 10 (supplement 3), 2005.


  163. Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, Partin AW, Sidransky D. Promoter hypermethylation as an independent prognostic factor for relapsein patients with prostate cancer following radical prostatectomy. Clin Cancer Res. 2005 Dec 1;11(23):8321-5.


  164. Ryan CJ, Eisenberger MA. Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?". J Clin Oncol. 2005 Nov 10;23(32):8242-6. Review.


  165. Armstrong AJ, Eisenberger MA. Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture? Nat Clin Pract Urol. 2006 May; 3 (5):246-7.


  166. Eisenberger MA, Sinibaldi VJ. The role of cytotoxic chemotherapy in prostate cancer. A critical reevaluation 20 years later. Oncology (Williston Park). 2006 Jul;20(8):853-62;discussion 863, 867-8 Review.


  167. Sinibaldi VJ, Elza-Brown K, Schmidt J, Eisenberger MA, Rosenbaum E, Denmeade SR, Pili R, Walczak J, Baker SD, Zahurak M, Carducci MA. Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. AM J Clin Oncol. 2006 Aug;29(4):395-8.


  168. Eisenberger MA. Treatment of Prostate Cancer in the 21st Century-Future Directions. Euro Assoc of Urology 2006 Sept; 5 (15):825-9.


  169. Montie JE, Abrahams NA, Bahnson RR, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG; National Comprehensive Cancer Network. Blaccer cancer. Clinical guidelines in oncology. J Natl Canc Netw. 2006 Nov;4(10):984-1014.


  170. Bajaj GK, Zhang A, Garrett-Mayer EL, Drew R, Sinibaldi VJ, Pili R, Denmeade SR, Carducci MA, Eisenberger MA, DeWeese TL. Phase II Study of Imatinib Mesylate in Patients with Prostate Cancer with Evidience of Biochemical Relapse After Definitive Radical Retropubic Prostatectomy or Radiotherapy. Urology. 2007 Mar;69(3):526-31.


  171. Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger MA. Adjuvant Weekly Docetaxel for Patients with High Risk Prostate Cancer After Radical Prostatectomy: A Multi-Institutional Pilot Study. J Urol. 2007 May;177(5):1777-81.


  172. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger MA, Dorey FJ, Walsh PC, Partin AW. Death in Patients with Recurrent Prostate Cancer After Radical Prostatectomy: Prostate-Specific Antigen Doubling Time Subgroups and Their Associated Contributions to All-Cause Mortality. J Clin Oncol. 2007 May 1;25(13):1765-71.


  173. Bastian PJ, Palapattu GS, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG. Prognostic Value of Preoperative Serum Cell-Free Circulating DNA in Men with Prostate Cancer Undergoing Radical Prostatectomy. Clin Cancer Res 2007 Sep 15;13(18):5361-5367.


  174. Collins C, Carducci MA, Eisenberger MA, Isaacs JT, Partin AW, Pili R, Sinibaldi VJ, Walczak JS, Denmeade SR. Preclinical and Clinical Studies with the Mult-Kinase Inhibitor CEP-701 as Treatment for Prostate Cancer Deomonstrate the Inadequacy of PSA Response as a Primary Endpoint. Cancer Biology & Therapy Vol 6:9,Sept 2007:1360-1267.


  175. Eisenberger MA, Sandler HM. Assessing and Treating Patients with Increasing Prostate Specific Antigen Following Radical Prostatectomy. The Journal of Urology 2007 Sept;178:S20-S24.


  176. Kantoff Pw, Beer TM, D’Amico Av, Dipaola RS, Eisenberger MA, Hussain MH, Kelly WK, Mathew P, Morris MJ, Ryan CJ, Sandler HM, Thompson IM, Carroll PR. Innovations and challenges in prostate cancer: Summary statement for the 6th Cambridge Conference. J Urol. 2007 Sep;178(3 Pt 2):S5-8; quiz S4. Epub 2007 Jul 20.


  177. Armstrong AJ, Garrett-Mayer E, OuYang YC, Carducci MA, Tannock I, deWit R, Eisenberger, MA. Prostate-Sepcific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer. J Clin Oncol Vol 25;2007:3965-3970.


  178. Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice. Localized Prostate Cancer. N Engl J Med 2007 Dec 27;357(26):2696-705.


  179. Armstrong AJ, Garrett-Mayer, E, Ou Yang Y, de Wit R, Tannock IF, Eisenberger MA. A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastic Prostate Cancer: A TAX327 Study Analysis. Clin Cancer Res 2007;13(21):6396-6403.


  180. Antonarakis ES, Blackford AL, Garrett-Mayer E, Eisenberger MA. Survival in Men with Nonmetastatic Prostate Cancer Treated with Hormone Therapy: A Quantitative Systematic Review. J Clin Oncol Vol 25;2007:4998-5008.


  181. Makarov DV, Humphreys EB, Mangold LA, Carducci MA, Partin AW, Eisenberger MA, Walsh PC, Trock BJ. The Natural History of Men Treated with Deferred Androgen Deprivation Therapy in Whom Metastatic Prostate Cancer Developed Following Radical Prostatectomy. J Urol. 2008 Jan;179(1):156-61.


  182. Bastian PJ, Palapattu GS, Yegnasubramanian S, Rogers CG, Xiaohui L, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG. CpG Island Hypermethylation Profile in the Serum of Men with Clinically Localized and Hormone Refractory Metastatic Prostate Cancer. J Urol. 2008 Feb;179(2):529-34.


  183. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 1;26(7):1148-59.


  184. Galsky MD, Eisenberger MA, Moore-Cooper S, Kelly K, Slovin SF, DeLaCruz A, Lee Y, Webb IJ, Scher HI. Phase I Trial of the Prostate-Specific Membrane Antigen-Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2008 May 1;26(13):2147-54.


  185. Armstrong AJ, Garrett-Mayer EL, Eisenberger MA. Re: Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens. J Natl Cancer Inst. 2008 May 7;100(9):681-2.9


  186. Eisenberger MA. Evolving new treatments for patients with prostate cancer: The advanced disease paradigm of the PSA era. Urol Oncol.2008 Jul-Aug;26(4):406-7.


  187. Rathkopf D, Carducci MA, Morris MJ, Slovin SF, Eisenberger MA, Pili R, Denmeade SR, Kelsen M, Curley T, Halter M, Collins C, Fleisher M, Heller G, Baker SD, Scher HI. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol. 2008 Jun 20;26(18):2959- 65.
  188. Wang W, Tavora F, Sharma R, Eisenberger MA, Netto GJ. PSMA expression in Schwannoma: A potential clinical mimicker of metastatic prostate carcinoma. Urol Oncol. 2008 Jun 3.


  189. Sartor AO, Tangen CM, Hussain MH, Eisenberger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D, Crawford Ed; Southwest Oncology Group. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer. 2008 Jun;112(11):2393-400.


  190. Antonarakis ES, Eisenberger MA. Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer?
    Nat Clin Pract Urol. 2008 Sep;5(9):480-1.


  191. Eisenberger, MA. Treat Early or Wait? A Stubborn Question that Remains Unanswered. Eur Urol. 2008 Oct 8.


  192. Guzzo TJ, Rogers CG, Deng CY, Bivalacqua TJ, Palapattu GS, Bastian PJ, Eisenberger MA, Schoenberg MP, Gonzalgo ML. Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastic disease. BJU Int. 2008 Dec;102(11):1539-43.


  193. Eisemberger MA. Words of wisdom. Re: Phase I clinical trial of selective inhibitor of CYP17, Abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkered E, Clark J, Cooper C, Kaye S, Dearnaley D, Lee G, de Bono JS.


  194. Antonarakis ES, Eisenberger MA. Is abiraterone acetate well tolerated and e effective in the treatment of castration-resistant prostate cancer? Nat Clin Pract Oncol. 2009 Jan;6(1):12-3.


  195. Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TF; National Comprehensive Cancer Network. Bladder cancer. J Natl Compr Canc Netw. 2009 Jan;7(1):8-39.


  196. Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH, Bieberich CJ, Hicks JL, Eisenberger M, Nelson WG, Mostwin JL, De Marzo AM. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate. 2009 May 1;69(6):603-9.


  197. Kejzman D, Eisenberger MA. LHRH antagonists vs LHRH agonists: which is more beneficial in prostate cancer therapy? Oncology (Williston Park). 2009 Jun;23(7):631-2.


  198. Kelloff GJ, Choyke P, Coffey DS; Prostate Cancer Imaging Working Group. Challenges clinical prostate cancer: role of imaging. AJR Am J Roentgenol. 2009 Jun;192(6):1455-70.


  199. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, Nelson WG, Yegnasubramanian S, Luo J, Wang Y, Xu J, Isaacs WB, Visakorpi T, Bova GS. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009 Jul;15(7):819.


  200. Antonarakis ES, Carducci MA, Eisenberger MA. Novel targeted therapeutics for Metastatic castration-resistant prostate cancer. Cancer Lett. 2009 Aug 28. [Epub ahead of print]


  201. Diaz LA Jr, Messersmith W, Sokoll L, Sinibaldi V, Moore S, Carducci M, Eisenberger M. TNF-blockade in patients with advanced hormone refractory prostate cancer. Invest New Drugs. 2009 Oct 21. [Epub ahead of print]


  202. Lin J, Sinibaldi VJ, Carducci MA, Denmeade S, Song D, Deweese T, Eisenberger MA. Phase I trial with a combination of docetaxel and (153) Sm-lexicronam in patients with castration-resistant metastatic prostate cancer. Urol Oncol. 2009 Dec 3.


  203. Armstrong JA, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger MA. Prediction of Survival Following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer. Clin Cancer Res. 16(1) 2010 Jan 16(1):1-9.


  204. Resta LP, Pili R, Eisenberger MA, Spitz A, King S, Porter J, Franke A, Boinpally R, Carducci MA, Sweeney CJ. A Phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Cancer Chemother Pharmacol. 2010 May 6 [Epub ahead of print]


  205. Keizman D, Eisenberger MA. Is there a role for chemotherapy in nonmetastic prostate cancer? Current Opinion in Supportive and Palliative Care. 2010 4:141-146.


BOOK CHAPTERS

  1. Eisenberger M, Hoth D, and Posada J. New drug development in head and neck cancer. In: Head and Neck Oncology. Wolf G, (ed), Boston, Massachusetts: Martinus Nuhoff Publishers, 1984.

  2. Eisenberger M, Posada J, Soper, and Wittes, RE. The current status of chemotherapy. In: Head and Neck Cancer. Wittes, R.E. (ed.), John Wiley and Sons, Ltd. Publishers, 1985.

  3. Marsoni S, Hurson S, and Eisenberger M. Chemotherapy for bone metastasis. In: Bone Resorption, Metastasis and Diphosphonates. S. Garatini (ed.), Raven Press, New York, New York, pp. 181-194, 1985.

  4. Eisenberger MA, Jacobs M, Drake K, Bajaj K, Kennedy P, Elias G, and Gray W. Simultaneous treatment with carboplatin (CBDCA) and conventional radiotherapy for unresectable loco-regional squamous cell carcinoma of the head and neck: Phase I-II Study. In: Head and Neck Oncology Research(editors Wolf GT and Carey TE), p 431-435, 1988.

  5. Eisenberger M. Endocrine resistant prostatic cancer: An Assessment of non-hormonal chemotherapy. In: Actualizaciones Urological. Mello N, Zwegen E, Pontes E (eds.), Barcelona, Spain, pp. 119-143, 1989.

  6. Parnes H, and Eisenberger M. Hormone releasing factors: Oncological uses. In: Proteins and Peptides as Drugs. Nadler, P.I., (ed). Marcell Dekker, Inc., 1989.

  7. Eisenberger M. Chemotherapy for head and neck cancer. In: Cancer of the Head and Neck. Second Edition. Suen, Myers (eds.), Churchill Livingstone Publishers, pp. 979-1004, 1989.

  8. Resnick M, Bagshaw M, Dorr F, Garnick M, Horton J, Prout G, Stamey T, Scardino P, Eisenberger M, Gibbons R, Kaplan W, Karr J, Tori F, and Trump D. Response/ progression criteria for evaluating prostate cancer. In: Diagnostic Ultrasound of the Prostate. Resnick, Watanabe, Karr (eds). Elsevier (publ.) pp. 88-97, 1989.

  9. Eisenberger M.: Chemotherapy in prostate cancer. In: "Current Genito-Urinary Cancer Surgery." Crawford ED, Das S (eds). Lea & Febiger, pp. 507-518, 1990.

  10. Eisenberger M, Chemotherapy for endocrine resistant cancer of the prostate. In: Treatment of Prostatic Cancer: Facts and Controversies. F. Schroder (ed). Wiley-Liss (Publisher), EORTC Monograph 8:155-164, 1990.

  11. Eisenberger M, Crawford E, McLeod E, Benson R, Spaulding J, Dorr A, Blumenstein B, Doppelblinde, Prospective Vergleischstudies Von Leuprorelin versus Leuprorelin plus Flutamide, In: der behandlung des Fortgeschrittenen Prostatakarzinoms. Frohmuller HBW, Wirth MP 9eds). Springer-Verlag (publisher), pp. 41-51, 1990.

  12. Belani C, Egorin M, Abrams J, Hiponia D, Eisenberger M, Aisner J, Van Echo D. A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide. In:Carboplatin (JM-8): Current Perspectives and Future Directions. (Bunn PA, Canetta R, Ozols R, Rosencweig M, (eds).) W.B. Saunders Co. Philadelphia, pp. 39-48, 1990.

  13. Eisenberger M. Male genital cancers: prostate and testicle. In: Cancer: A Technical Monograph M. Mitchell (ed). National Labs (publisher), pp 29 - 35, 1991.

  14. Eisenberger M. Chemotherapy for advanced prostate cancer. In: Monographs of the European School of Oncology on The Medical Management of Prostate Cancer L. Denis (ed) Springer-Verlag publishers, NY, pp. 75-87, 1991.

  15. Belani C, and Eisenberger M. Carcinoma epdermoide de cabeza e cuello locamente avanzado e irresecable: Tratamintos combinados con quimiotherapia y radioterpia conventional sincronicas. Avances en Cancer de Cabeza Y Cuello. Baron, SMAR Madrid, Spain, Capitulo 13, pp 183-188, 1992.

  16. Eisenbeger MA. Chemotherapy for Carcinomas of the Penis and Urethra. In: The Uriologic Clinics of North America. (eds) Crawford ED, Das S. W.B. Saunders Company, Vol 19, (2): pp 333-338, 1992

  17. Belani C, Eisenberger M. Quimiotherapia en el carcinoma epidermoids de cabeza y cuello. In: Advances En Cancer De Cabeza Y Cuello. (ed). Gonzales Baron, SMAR, Madrid, Spain, pp 205-214, 1992.

  18. Aisner J, Eisenberger M, and Fontanta J. Hormonal Agents. Section Two: Chemotherapy Drugs. In: The Chemotherapy Source Book. M.J. Perry (ed). Williams & Wilkins pp. 413-429, 1992.

  19. Eisenberger M, and Parnes H. Use of GNRH analogues in oncology: prostate and breast cancer, In: Gonodotropin Hormone Releasing Hormone Analogues, In: Infertility and Reproductive Medicine Clinics of North America. (Ed. M.L. Polan, M.R. Henzl), Vol. 4, (1):171-188, 1993

  20. Eisenberger M. Chemotherapy and Palliation in Prostate Cancer. In: Cancer of the Prostate. Crawford ED, Das S (eds). Marcell Dekker Inc., Chapter 17.pp 369-398, 1993.

  21. Eisenberger M. Genito-urinary malignancies, In: Oncology - Current Practice of Medicine (Volume Editor Ettinger D.), Volume 3, Section (12): 7.1-7.10, 1996.

  22. Aisner J, Fram R, Eisenberger M, and Fontana J. Hormonal agents for the treatment of cancer, In: The Chemotherapy Source Book. 2nd edition, (Williams & Wilkins, Balto., MD, Michael C. Perry, Editor) pg. 459-476, 1996.

  23. Eisenberger M. Chemotherapy for cancer of the prostate, In: Current Genito Urinary Cancer Surgery, ED Crawford), second edition, section XII (52), pg 667-677, 1996.

  24. Carducci M, Eisenberger M, Kobayashi K, Reyno L, and Egorin M. Suramin in advanced prostate cancer. In: Comprehensive Text Book of Genito-Urinary Oncology. Chapter 18c, Section 2. 1996

  25. Eisenberger M. Chemotherapy for hormone-resistant prostate cancer, In: Campbell’s Urology , (Walsh, Retik, Vaughn, Wein(Eds), Saunders(publ.), 7th Edition, vol. 3, Chapter 90, pg. 2645-2658, 1997.

  26. Mahler C, Akaza H, Boccardo F, Coulange C, DiSilverio F, Eisenberger M, Jakse G, Tunn U, Varkarakis M, Verhelst J. Chapter 10. Secondary hormonal treatment. In: Proceedings of the First International Consultation on Prostate Cancer. (Murphy G, Denis L, Chatelain C, Griffiths K, Khoury S, Cockett, Scientific Communications International) pg. 305-324, 1997.

  27. Eisenberger MA. Chemotherapy for Hormone-Resistant Prostate Cancer. In: Campbell’s Urology, Study Guide (Walsh PC, Retik AB, Vaughan ED, Wein AJ, Editors. Saunders Publisher) Vol 3, Section XI, Chapter 90, pg. 2645-2658 1998.

  28. Eisenberger MA. Chemotherapy for Hormone-Resistant Prostate Cancer. In: Campbell’s Urology, 7th Edition (Walsh PC, Retik AB, Vaughan ED, Wein AJ, Editors) Chapter 91, p 373, 1998.

  29. Eisenberger MA. New Approaches To Drug Development in Prostate Cancer. In: Renal, Bladder and Prostate Cancer An Update. Ed. Karl Kurth, Gerald Mickisch and Fritz Schroder, Parthenon Publishing (PACIO V - 1998), Section 3, Chapter 24: 211-218, 1999.

  30. Rubben H, Schmidt J.D., Eisenberger M, Lluch I, Pienta K.J. and Logothetis C. Treatment of Hormone Resistant Disease. In: Prostate Cancer. Ed. G. Murphy, S. Khoury, A. Partin and L. Denis, Chapter 11, pg 409-435, 2000.

  31. Schoenberg, MP, Bluemke DA, Carducci MA, DeMarzo AM, DeWeese TL, Eisenberger MA, Mandavili S, Rosenthal DL, Sinibaldi VJW, Walker JM, Willmann J, and Wills Marcia. The Guide to Living with Bladder Cancer, 2000.

  32. Eisenberger MA. Non-Endocrine Systemic Approaches For Prostate Cancer: Current Status And Future Directions. In: Renal, Bladder and Prostate Cancer An Update. Ed. Fritz Schroder, Parthenon Publishing. Chapter 24, pg 219-228, 2001.

  33. Eisenberger MA and Carducci M. Chemotherapy for hormone-resistant prostate cancer, In: Campbell’s Urology, (Walsh, Retik, Vaughn, Wein (Eds), Saunders (publ.), 2th Edition, Chapter 95, pg 336-339, 2002.

  34. Carducci M, Gilbert J, Bowling K, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen T, Grochow L and Donehower R. A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on a 120-h infusion schedule. Clin Cancer Res 2001; 7:3047-3055.

  35. Eisenberger MA, and Carducci MA. Chemotherapy for Hormone-Resistant Prostate Cancer, Ed. G. Murphy, S. Khoury, A. Partin and L. Denis, Vol. 4, Chapter 95, pg 3209, 2002.

  36. Eisenberger MA Prostate Cancer. In: Clinical Oncology, (Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG. 3rd Edition, Chapter 87, pg 2085-2148, 2004.


  37. D’Amico AV, Eisenberger MA, Partin AW, Pienta KJ.  Therapeutic Strategies for Patients With a Rising PSA:  A Case-Based Approach.  Report to the Nation on Prostate Cancer. Chapter 9, pg 85-92, 2004.

  38. Eisenberger MA. Controversies in hormone treatment for prostate cancer, In: Prostate Cancer, Principles & Practice. Nartub Dybutz Ktd (Taylor & Francis Group). Section F, Chapter 32, 2005./li>

  39. Eisenberger MA and Carducci MA. Chemotherapy for Hormone-Resistant Prostate Cancer, In: Campbell-Walsh Urology. Wein AK. Kavoussi LR, Novick AC, Partin AW and Peters CA (eds). Elsevier (publ) 9th Edition, Chapter 105.

  40. Nelson, W.G., Saad, F., Debruyne, F.M.J.,Eisenberger MA., Fourcade, R., Frenkel, E.P., Kantoff, P.W., Kumon, H., Nasu, Y., Oudard, S., and Wirth, M. Chaper 10: Committee 13, new therapeutic targets and treatments for metastatic prostate cancer. In Prostate Cancer, McConnell, J., Denis, L., Akaza, H., Khoury, S., and Schalken, J. (Eds.), Health Publications, Editions 21, Paris, France (2006).

  41. Eisenberger MA. The Current Knowledge of Hormonal Therapy in the Treatment of Prostate Cancer. Current Clinical Oncology: Prostate Cancer: Signaling Networks, Genetics and New Treatment Strategies. (2007




ABSTRACTS

  1. Kaplan R, Eisenberger M, Silverman M, and Lessner H. Four-drug combination chemotherapy of advanced GI malignancy. Digestion 16:249, (Israel - 1977).

  2. Eisenberger M, Denefrio J, Mansell P, and Silverman M. Combination chemotherapy with bleomycin and hydroxyurea in advanced head and neck cancer. Presented at the U.I.C.C. Meeting, Buenos Aires, Argentina, Proceedings U.I.C.C., 1978.

  3. Eisenberger M, Denefrio J, Kaplan D, Silverman M, and Lessner H. Combination chemotherapy with bleomycin and hydroxyurea in advanced head and neck cancer. Proc Am Soc Clin Oncol/Am Assoc Cancer Research, 21:343(C-97), San Diego, 1980.

  4. Eisenberger M, Pereiras R, Solomon J, and Lessner H. Combination chemotherapy with cis-dichlorodiammine-platinum (DDP) and cytosine arabinoside (CA) given by intra-arterial (IA) or intravenous (IV) infusion in patients (Pts) with metastatic colorectal cancer. Proc Am Assoc Cancer Research/Am Soc Clin Oncol 22:453, 1981.

  5. Kumar K, Eisenberger M, Broder L, and Love N. Non-pulmonary small cell carcinoma (SCC): Response to combination chemotherapy (CT). Proc Am Assoc Cancer Research/Am Soc Clin Oncol 22:528, 1981.

  6. Warner B, Santen R, Demers L, Max D, Lohman P, Smith J, Muss H, Resnick M, Glode M, Wettlaufer J, Eisenberger M, and Block N. Effects of (D-LEU6DES-GLY-NH210, pro-ethylamide9) GnRH (LEUPROLIDE) pm steroidogenesis when used to treat prostatic carcinoma. Proc Am Assoc Andrology, 1981.

  7. Eisenberger M. Chemotherapy of salivary gland tumors - A preliminary report. Proc Florida Society Clinical Oncology, 1982.

  8. Eisenberger M, Ariel M, Broder L, Allen L, and Diamonti G. Comprehensive Cancer Center for the State of Florida, University of Miami School of Medicine, Florida A & M University, and V.A. Medical Center, Miami, Florida. Phase I-II of guanazole (GZ) by intermittent intravenous (IV) infusion in patients with advanced carcinoma (CA). Proc 13th International Cancer Congress, 1982.

  9. Vogel CL, Gorowski E, and Eisenberger MA. Phase I trial of weekly ICRF-187. Proc Am Soc Clin Oncol, 1982.

  10. Warner B, Santen R, and members of the Abbott Study Group. Successful "Medical Castration" with a superagonist analog of gonadotropin releasing hormone (GnRH) in treating prostatic carcinoma. Proc Am Soc for Clin Invest, 1982 (Presented by Warner, B.)

  11. Glode L (for the Abbott Prostatic Cancer Study Group). Leuprolide therapy of advanced prostatic cancer, Proc Am Soc Clin Oncol, 1982.

  12. Singer J, Eisenberger M, Block N, and Politano V. A comparison of prostate cancer treated with GnRH or DES. Poster presentation. Proc Am Urological Assoc, New Orleans, 1984.

  13. Singer J, Block N, Eisenberger M, and Politano V. A comparative analysis of a gonadotropin releasing hormone and diethylstilbestrol. Presented at the South Section of Am Urological Assoc, Atlanta, 1984.

  14. Eisenberger M, Ellenberg S, Jones B, and Friedman M. The advantages of early stopping rules in randomized trials for head and neck cancer. Proc Am Soc Clin Oncol C-520: 134, 1985.

  15. Kalash S, Eisenberger M, Henzl M, and Hoffman. Effective sustained androgenic suppression with (D-Nal(2)6-LHRH) agonist. Proc Am Urological Assoc, National Meeting, New York, N.Y., 396:203(a), 1986.

  16. Eisenberger M, Silva H, Kalash S, Henzl M, Hoffman P, and Members of the Nafarelin Study Group. Effective long-term androgenic suppression and clinical benefits with nafarelin acetate: a new intranasal LHRH analog for prostatic cancer. Proc Am Soc Clin Oncol, C-417, 1986.

  17. Silva H, Abrams J, Olver I, Eisenberger M, Tchekmedyian N, Leavitt R, Abrams J, and Aisner J. Phase II trial of n-methylformamide in patients with unresectable or recurrent renal cell carcinoma. Proc Am Soc Clin Oncol 357:92, 1986, Los Angeles.

  18. Tchikmedyian N, Kaplan R, Elias E, Eisenberger M, Abrams J, and Van Echo D. Phase II study of n-methyloformamide in colorectal cancer. Proc Am Soc Clin Oncol 416:107, 1986, Los Angeles.

  19. Conley B, Silva H, Hornedo J, Eisenberger M, and Aisner J. Phase II Trial of 4'deoxdoxorubicin in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 727:185, 1986, Los Angeles.

  20. Crawford D, McLeod D, Spaulding J, Benson R, Eisenberger M, and Blumenstein B. A comparison of leuprolide with flutamide and leuprolide in previously untreated patients with clinical stage D2 cancer of the prostate, phase III – Intergroup - 0036. Proc AUA 610:256(A), 1987.

  21. Eisenberger M, Bajaj K, Kennedy P, Jacobs M, Elias G, and Gray W. Phase I-II study of simultaneous rt and weekly carboplatin for unresectable head and neck cancer. Proc Am Soc Clin Oncol 531:135, 1987.

  22. Kennedy P, Eisenberger M, et al. Toxicity with carboplatin in combination with methotrexate in patients with recurrent head and neck cancer. Proc Am Soc Clin Oncol 533:136, 1987.

  23. Eisenberger M, Jacobs M, Bajaj K, Kennedy P, Drake K, Elias G, and Gray W. Simultaneous treatment with carboplatin (CBDCA) and conventional radiotherapy for the treatment of patients with advanced unresectable squamous cell carcinoma of the head and neck. Preliminary results of a phase I-II trial. Proc Second International Head and Neck Oncology Research Conference, Abst. No. 1.9, Arlington Virginia, September 1987.

  24. Crawford D, McLeod D, Dorr A, Spaulding J, Benson R, Eisenberger M, and Blumenstein B. A comparison of leuprolide with flutamide and leuprolide in clinical stage D2 cancer of the prostate. South Central Section of the Am Urological Association (1987).

  25. Kelsen D, Nanus D, Lipperman R, and Eisenberger M. Phase II trial of ifosfamide in epidermoid of the esophagus. Proc Am Soc Clin Oncol 340:1987, Atlanta.

  26. Belani C, Van Echo D, Eisenberger M, Conley B, Hiponia D, Markus S, and Aisner J. A Phase II study of caracemide in advanced or recurrent non-small cell lung cancer. Proc Am Soc Clin Oncol 708:180, 1987, Atlanta

  27. Melink T, Van Echo D, Tait M, Abrams J, Eisenberger M, and Aisner J. Phase II trial of caracemide (NSC253272) administered by 5-day continuous infusion in advanced colorectal carcinomas. Proc Am Soc Clin Oncol 438:114, 1988.

  28. Tait N, Abrams J, Egorin M, Cohen A, Eisenberger M, and Van Echo D. Phase II carboplatin (CBCDA) for metastatic renal cell cancer with a standard dose and a calculated dose according to renal function. Proc Am Soc Clin Oncol 484:125, 1988.

  29. Belani C, Abrams J, Egorin M, Eisenberger M, Hiponia D, Van Echo DA, Schimpff SC, and Aisner J. Phase II study of carboplatin and etoposide for non-small cell lung cancer using pharmacologically based dosing. Proc Am Soc Clin Oncol 829:214, 1988.

  30. Eisenberger M, Krasnow S, and Ellenberg V. A comparison of carboplatin and methotrexate vs. MTX in recurrent head and neck cancer. Proc Am Soc Clin Oncol 504:153, 1988.

  31. Sinibaldi V, Eisenberger M, Jacobs M, Engstrom C, Elias G, Drake K, Gray W, Van Echo D, and Abrams J. Simultaneous carboplatin and conventional radiotherapy in advanced unresectable squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol, 503:153, 1988.

  32. Crawford E, McLeod D, Dorr A, Spaulding J, Benson R, Eisenberger M, and Blumenstein B. Treatment of newly diagnosed stage D2 prostate cancer with leuprolide and flutamide or leuprolide alone. Phase III - intergroup, study 0036, Proc Am Soc Clin Oncol, 460:119, 1988. (Presented at the plenary session - 5-selected abstracts/year).

  33. Crawford E, McLeod D, Dorr A, Spaulding J, Benson R, Eisenberger M, and Blumenstein B. Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone. Phase III-Intergroup, study 0036, Proc Am Urology Assoc, 4,706:139, 1988, Boston, MA.

  34. Jacobs M, Eisenberger M, Sinibaldi V, Gray W, and Salazar O. Carboplatin and radiotherapy for stage IV carcinoma of the head and neck. Radiation Oncology, Physics, 15:138(44), 1988. Presented by Dr. Jacobs at the Am Soc Therap Rad Oncol Meeting in New Orleans, Louisiana.

  35. Van Echo D, Hiponia D, Abrams J, Eisenberger M, Kaplan R, and Aisner J. A phase II study of IPROPLATIN (CHIP) in advanced malignant melanoma. Proc Am Soc Clin Oncol 984:754, 1988.

  36. Eisenberger M, Crawford E, Benson R, McLeod D, Dorr A, and Spaulding J. Significance of pretreatment stratification by extent of disease in stage D2 prostate cancer patients treated with leuprolide + flutamide or leuprolide + placebo. Presented at the Am Soc Clin Oncol, 1989,San Francisco.

  37. Sinibaldi V, Eisenberger M, Jacobs M, Elias G, Abrams J, Gray W, Van Echo D, and Aisner J. Simultaneous carboplatin and radiation therapy for unresectable stage IV head and neck cancer. Presented by V. Sinibaldi, Am Soc Clin Oncol, 1989 San Francisco.

  38. McLeod D, Blumenstein B, Eisenberger M, Crawford E, Spicer D, Spaulding D, Dorr A, and Benson R. Evaluation of complete androgen blockade with flutamide added to euprolide after progression to leuprolie alone. Proc Am Soc Clin Oncol, A-526 p.136, 1990, Washington D.C.

  39. Eisenberger M, Blumenstein B, and Crawford E. Evaluation of chemotherapy in prostate cancer patients with measurable versus bone disease only. Proc Am Soc Clin Oncol, A-596, p.153, 1990, Washington, D.C.

  40. Kruter F, Sinibaldi V, Engstrom C, Abrams J, Jacobs M, and Eisenberger M. Phase II trial with IV 6-thioguanine in recurrent head and neck. Proc Am Soc Clin Oncol A-700, p. 181, 1990, Washington, D.C.

  41. Belani C, Hiponia D, Engstrom D, Fishbein G, Eisenberger M, and Aisner J. Combination of mitoxantrone and cisplatin for patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol A-924, 1991, Houston, Texas.

  42. Jacobs M, Eisenberger M, Sinibaldi V, Belani C, and Gray W. Simultaneous treatment with carboplatin, bleomycin and radiation therapy for unresectable head and neck carcinomas. Proc Am Soc Clin Oncol A-691, p. 207, 1991, Houston, Texas.

  43. Jodrell D, Zuhowski E, Egorin M, Sinibaldi V, Forrest S, and Eisenberger M. Intermittent bolus dosing with suramin: the use of adaptive control with feedback (ACF). Proc Am Soc Clin Oncol A-237, p.92, 1991, Houston, Texas.

  44. Crawford E, Moon T, Stone M, Blum D, Becker M, Bergen R. Eisenberger M, et al. Prostate Cancer Awareness Week. Proc Am Soc Clin Oncol A-531, p.167, 1991, Houston, Texas.

  45. Eisenberger M, Jodrell D, Sinibaldi V, Zuhowski E, Jacobs S, and Egorin M. Preliminary evidence of anti-tumor activity against prostate cancer in a phase I trial with suramin. Proc Am Soc Clin Oncol A-537, p.168, 1991, Houston, Texas.

  46. Eisenberger M, Melink T, Thompson R, Reyno L, Sinibaldi V, et al. Changes in serum PSA levels in patients (PTS) with hormone refractory prostate cancer (HRPCa) treated with suramin. Am Urol Assoc, Inc. (October 1, 1991).

  47. Eisenberger M, Sinibaldi V, Jodrell D, Reyno L, et al. Activity of suramin in hormone refractory prostate cancer (PC): University of Maryland experience. Am Urol Assoc, Inc. (October 1, 1991).

  48. Eisenberger M, Crawford E, Blumenstein B, Dorr A, McLeod D, and Wolf M. Leuprolide with or without flutamide for stage D2 prostate cancer: Prognostic significance of minimal disease. Am Soc Clin Oncol 1992 San Diego, California.

  49. Crawford E, Eisenberger M, McLeod D, and Blumenstein B. Treatment of newly diagnosed stage D2 prostate cancer with leuprolide and flutamide or leuprolide alone. American Urological Association, 1992 Washington DC.

  50. Eisenberger M, Sinibaldi V, Tkaczuk K, Reyno L, Jacobs S, and Egorin M. Activity of suramin in hormone refractory prostate cancer: Phase I. Am Urol Assoc, 1992 Washington, D.C.

  51. Tkaczuk K, Eisenberger M, Reyno L, Sinibaldi V, and Egorin M. Preliminary activity of suramin in hormone refractory prostate cancer. Am Soc Clin Oncol, 1992 San Diego, California.

  52. Eisenberger M, Reyno L, Sinibaldi V, et al. Predictive value of PSA changes in prostate cancer on Suramin. Am Soc Clin Oncol, 1993, Orlando, Florida.

  53. Staggers F, DeAntoni E, Crawford E, Stone N, Blum D, Berger R, Eisenberger M, and Gambert S. A profile of African-american participants in prostate cancer awareness week, 1992. Proc. Am Urol Assoc, (Abstr. 255, 2q1 A,) 1994, San Francisco, CA.

  54. Reyno L, Eisenberger M, Sridhara R, Sinibaldi V, and Egorin M. Safety and efficacy of a pharmacologically derived fixed treatment schedule of suramin in stage D3 prostate cancer. Proc Am Soc Clin Onc, (Abstr 729 p.236,) 1994, Dallas ,Texas.

  55. Aisner J, Jacobs M, Gray W, Sridhara R, Sinibaldi V, Belani C, and Eisenberger M. Weekly carboplatin and weekly, carboplatin with twice-weekly bleomycin each with concurrent RT for locally advanced head and neck cancer. Proc Am Soc Clin Onc (Abstr #0, 02, p.280,) 1994.

  56. Eisenberger M, Sinibaldi V, Reyno L, and Sridhara R. Development of an active and tolerable out patient schedule of Suramin for patients with hormone refractory prostate cancer Proc. Am Urol Assoc Abst. #43, 238A, 1994, San Francisco, CA

  57. Crawford E, Eisenberger M, Blumenstein B, McLeod D, Culkin D, Bueschen A, Thompson J, and Lowe B. Treatment of histologically confirmed D2 prostate cancer. A comparison of bilateral orchiectomy with or without flutamide (intergroup study 0150). Proc Am Urol Assoc (Abst. #44, 238-A,) 1994, San Francisco, CA

  58. Stone N, Blum D, DeAntoni E, Crawford E, Schmid K, Eisenberger M, Berger R, Staggers F, and Gambert S. Prostate cancer risk factor analysis among > 50,000 men in a national study of PSA. Proc. Am Urol Assoc (Abst. #201, 278-A,) 1994, San Francisco, CA.

  59. Elder K, Eisenberger M, Sridhara R, Reyno L, Sinibaldi V, and Egorin M. Evaluation of a flutamide withdrawal factor on responses to suramin in stage D3 prostate cancer. Proc. American Society of Clinical Oncology, Abst.# 778, p.248, 1994.

  60. Hemady R, Sinibaldi V, and Eisenberger M. Ocular symptoms and signs associated with suramin treatment for metastatic cancer of the prostate (P022) Opthalmology 101(suppl): 91, 1994.

  61. Eisenberger M, Crawford E, McLeod D, Hussain M, Loehrer P, and Blumenstein B. The prognostic significance of prostate specific antigen (PSA) in stage D2 prostate cancer (PC) interim evaluation of intergroup study 0105. Proc. American Society of clinical Oncology, Abst.# 613, p. 235, 1995.

  62. DeAntoni E, Crawford E, Stone N, Blum D, Staggers F, Berger E, Eisenberger M, and Gambert S. A profile of Latino participants in prostate cancer awareness week. Am Urol Assoc, 1995, Las Vegas, NV.

  63. DeAntoni E, Ross C, Crawford E.D, Hirano D, Blum D, Berger E.R, Stone N, Eisenberger M, Gambert S, McLeod D. Time since vasectomy cannot be separated from age as risk for prostate cancer. South-Central Section, AUA, 1995.

  64. Chaudhry V and Eisenberger M. Suramin-induced peripheral neuropathy-clinical and electrophysiological features. The American Neurological Association, 1995.

  65. Sridhara R, Eisenberger M, Sinibaldi V, Reyno L and Egorin M. Evaluation of PSA as a surrogate endpoint for response of hormone refractory prostate cancer to suramin. Proc Am Soc Clin Oncol, 14:85(Abstr 40), 1995.

  66. Eisenberger M, Crawford ED, Blumenstein B, Hussain M and McLeod D. The prognostic significance of PSA in stage d2 patients. Proc Am Soc Clin Onc 14:235 (Abstr 613), 1995.

  67. DeAntoni E, Crawford E, Ross, Colleen A, Blum D, Berger E, Nelson N, Eisenberger M, Gambert S, McLeod D, Staggers F. Age and race-specific reference ranges for prostate-specific antigen from a large, community-based study. Am Urol Assoc, 1996, Orlando, FL.

  68. Small EJ, Marshall F, Natale R, Meyers F, Lenehan P, Boyea T, Eisenberger M. A multicenter phase III trial of suramin + hydrocortisone vs. placebo + hydrocortison in metastatic hormone-refractory prostate cancer: favorable safety profile. Proc Am Soc Clin Onc 15:254 (Abstr 655), 1996.

  69. Kucuk O, Blumenstein B, Moinpur C, Lew D, Coleman D, Eisenberger M and Crawford D. Phase II trial of casodex in advanced prostate cancer patients who failed conventional hormonal manipulation: a SWOG study. Proc Am Soc Clin Onc, 15:245(Abstr 618), 1996.

  70. Baker SD, Diasio R, Lucas VS, Khor SP, Thomas S, Sartorius S, Donehower R, Eisenberger M, Grochow L, O’Reilly S, Hohneker J and Rowinsky E. Phase I and pharmacologic study of oral 5-fluorouracil on a chronic 28-day schedule in combination with the DPD innactivator 776C85. Proc Am Soc Clin Oncol, 15:486(Abstr 547) 1996.

  71. Bowling M, Nelson J, Tong K, Simons J, Eisenberger M, Sinibaldi V, Donehower R, and Carducci M. Biomarker responses in men with advanced prostate cancer (PCA) to infusional phenylbutyrate (PB). Proc Amer Soc Clin Onc, Abst.# 43, p.94, 1996.

  72. Carducci M, Bowling M, Eisenberger M, Sinibaldi V, Simons J, Chen T-L, Noe D, Grochow L, and Donehower R. Phenylbutyrate (PB) for refractory solid tumors: a phase I clinical and pharmacologic evaluation. Proc Amer Soc Clin Onc, Abst. #1542, p.485, 1996.

  73. Harbaugh B, Roth B, Eisenberger M, Langleben A, Allen R, Rasmussen H. Marimastat, a novel matrix metalloproteinase inhibitor in patients with hormone-refractory prostate cancer. Proc Amer Soc Clin Onc 15:258(Abstr. 671) 1996.

  74. Carducci M, Bowling M, Eisenberger M, Sinibaldi V, Simons W, Chen T, Noe D, Grochow L, Donehower R. Phenylbutyrate (PB) for refractory solid tumors: a phase I clinical and pharmacologic evaluation. Proc Amer Soc Clin Onc 15:484(Abstr. 1542) 1996

  75. Bowling M, Nelson, J, Tong K, Simons J, Eisenberger M, Sinibaldi V, Donehower R, Carducci M. Biomarker responses in men with advanced prostate cancer to infusional phenylbutyrate. Proc Amer Soc Clin Onc 15:94(Abstr. 43) 1996.

  76. Kucuk O, Blumenstein B, Moinpour C, Lew D, Coleman D, Eisenberger M, Crawford D. Phase II trial of casodex in advanced prostate cancer patients who failed conventional hormonal manipulation: A SWOG Study. Proc Amer Soc Clin Onc 15:245(Abstr.618) 1996.

  77. DeAntoni E, Holthaus K, Crawford E.D, Stone N, Blum D, Berger E.R, Gambert S, Eisenberger M, Staggers F, and McCloud D. Prostate-Specific antigen (PSA) velocity in a national cohort tested serially with three annual tests. Proc Am Urol Assoc Annual Meeting, 157:57 (Abstr 216) April 1997.

  78. Cook D, Sinibaldi V, Carducci M, Schneyer C, Dobs A and Eisenberger M. Osteopenia in men with prostate cancer treated with androgen deprivation. Proc Am Urol Assoc Annual Meeting, 157:232 (Abstr 906) April 1997.

  79. Crawford E.D., Eisenberger M, McLeod D, Wilding G, and Blumenstein B. Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients with stage D2 adenocarcinoma of the prostate: results of NCI intergroup study. Proc Am Urol Assoc Annual Meeting, 157:336 (Abstr 1311) April 1997.

  80. Mosher T, Bluemke D, Fishman E, Schoenberg M, Eisenberger M, and DeWeese T. Multimodality treatment planning for bladder cancer: MR and CT evaluation. Am Reontgen Ray Soc Annual Meeting, May 1997.

  81. Eisenberger M, Crawford E.D, McLeod D, Loehrer P, Wilding G, and Blumenstein B. A comparison of bilateral orchiectomy (orch) with or without flutamide in stage D2 prostate cancer (PC) (NCI INT-0105 SWOG/ECOG). Proc Am Soc Clin Onc Annual Meeting, 16:2a (Abstr 3 plenary session), May 1997.

  82. Moinpour C, Savage M, Lovato L, Troxel A, Skeel R, Eisenberger M, Crawford E.D, Meyskens F, Jr. Quality of life endpoints in advanced stage prostate cancer: a randomized, double blind study comparing flutamide to placebo in orchiectomized stage D2 prostate patients. Proc Am Soc Clin Onc Annual Meeting 16:53a (Abstr 183), May 1997.

  83. Long G.S, Sinibaldi V, Carducci M, O’Reilly S, Grochow L, Noe D, and Eisenberger M. Phase I/II study of suramin and topotecan in patients with hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Onc Annual Meeting 16:242a (Abstr 855), May 1997.

  84. Cook D, Sinibaldi V, Carducci M, Schneyer C, Dobs A, Eisenberger M. Osteopenia in men with prostate cancer treated with androgen deprivation. Proc Am Soc Clin Onc Annual Meeting 16:312a (Abstr 1111), May 1997.

  85. Sinibaldi V, Carducci M, Abeloff M, and Eisenberger M. Experience with casodex in patients with stage D3 prostate cancer. Proc Am Soc Clin Onc Annual Meeting 16:313a (Abstr 1116), May 1997.

  86. Boasberg P, Harbaugh, Eisenberger M, Harris J, Langleben A, Ahmann F, Roth B, Berkheimer M, and Rasmussen H. Marimastat in patients with hormone-refractory prostate cancer: a dose-finding study. Proc Am Soc Clin Onc Annual Meeting 16:316a (Abstr 1126), May 1997.

  87. Sinibaldi, V.J., Long, G.S., Chaudhry, V., Carducci, M.A., Reyno, L.M., O’Reilly, S.Chen, T.L., Sridhara,R., and Eisenberger,M.A. Phase I and pharmacologic evaluation of a monthly, daily times five days (D), schedule (SCH) of suramin (S) in patients with hormone refractory prostate cancer (HRPC). Proceedings of the American Society for Clinical Oncology, 17(A- 841):218a, 1998.

  88. Long, G.S., Sinibaldi, V.J., O’Reilly, S., Carducci, M.A., Growchow, L.B., Reyno, L., Enger, c., and Eisenberger, M.A. Phase I and pharmacologic study of suramin (S) and Topotecan (T) in patients with hormone refractory prostate cancer (HRPC). Proceedings of the American Society for Clinical Oncology, 17(A- 948): 247a, 1998.

  89. Carducci, M., Bowling, M., Eisenberger, M., Sinibaldi, V.,Chen, T-L., Buckley, N., Grochow, L., Noe, D., and Donehower, R. Oral Sodium Phenylbutyrate (PB) for Refractory Solid Tumors: Phase I and Bioavailability Assessment. Proceedings of the American Society for Clinical Oncology, 17(A- 831):215a, 1998.

  90. Laufer, M., Sinibaldi, V., Wang, Z.P., Ts O, P., Partin, A., Carducci, M., and Eisenberger, M. Detection and phenotypic characterization of circulating prostate cancer cells in patients with metastatic hormone refractory prostate cancer (HRPC): A pilot evaluation. Proceedings of the American Society for Clinical Oncology, 18(A-1329): 345a, 1999.

  91. Sinibaldi, V., Carducci, M., Moore-Cooper, S., Enger, C., Laufer, M., Wolfe, A., and Eisenberger, M. A phase II study evaluating a one-day course of estramustine phosphate (EMP) and docetaxel (D) in patients (Pts) with hormone refractory prostate cancer (HRPC). Proceeding of the American Society for Clinical Oncology, 18(A-1239):322a, 1999.

  92. Sinibaldi, V.J., Carducci, M.A., Moore-Cooper, S., Laufer, M., and Eisenberger, M.A. A phase II study evaluating docetaxel (D) and one day of estramustine phosphate (EMP) in patients (PTS) with hormone refractory prostate cancer (HRPC): Updated preliminary analysis. Proceedings of the American Society for Clinical Oncology, 19:346a (1361), New Orleans, LA, 2000.

  93. Eisenberger, M., Sinibaldi, V., Laufer, M., and Carducci, M. Phase I / + pharmacokinetic evaluation of marimastat in patients (PTS) with advanced prostate cancer: identification of the biologically active dose. Proceedings of the American Society for Clinical Oncology, 19:336a (1320), 2000.

  94. Lieb II, J., Walters, R., Carducci, M., Eisenberger, J., DeWeese, G., Tang, T., Dobs, A.; Johns Hopkins University School of Medicine, Baltimore, MD; Tufts University School of Public Health, Boston, MA. Decreased bone density and increased bone resorption in men with prostate cancer who have been androgen deprived. Proceedings of the American Society for Clinical Oncology, 19:333a (1310), 2000.

  95. Laufer, M., Thortone, D., Eisenberger, M., Vogelzang, N., Mills, G., Raghavan, D.; Johns Hopkins University, Baltimore, MD; Eli Lilly and Company Indianapolis, IN; University of Chicago, Chicago, IL; University of Couth California, Los Angeles, CA. Phase I study of escalating doses of the dual-action 5-? reductase inhibitor LY320236 in patients (Pts) with advanced prostate cancer: preliminary clinical and hormonal results. Proceedings of the American Society for Clinical Oncology, 19:369a (1461), 2000.

  96. Sinibaldi, V., Carducci, M., Moore-Cooper, S., Laufer, M., Zahurak, M., and Eisenberger, M. A phase II study evaluating docetaxel (D) and one day of eatramustine phosphate (EMP) in hormone refractory prostate cancer (HRPC). Annals of Oncology: Abstract Book of the 25th ESMO Congress, 11 [suppl 4], # 341P, October, 2000. Hamburg, Germany.

  97. Sinibaldi, V., Laufer, M., Eisenberger, M., Vogelsang, N., Mills, G., Sartor, O., Raghavan, D. A multicenter Phase I/II Clinical and Pharmacological Evaluation of a Type I and II 5 Alpha Reductase Inhibitor (LY320236). Proceedings of the American Society for Clinical Oncology, 20:186a (743), San Francisco, California, 2001.

  98. Eisenberger, M., Laufer, M., Sokoll, L., Sinibaldi, V., Zahurak, M., Crawford, D. Sequential evaluation of multiple potential bio-markers in patients with metastatic prostate cancer (PCA) following androgen deprivation. Proceeding of the American Society for Clinical Oncology, 20:190a (758), San Francisco, California, 2001.

  99. Schrodr LE, Glass T, Eisenberger M, Culkin D, Buowski R, Crawford E; University of Cincinnati, OH. Proceeding of the American Society for Clinical Oncology, 20:153b (2361), San Francisco, California, 2001.

  100. Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinabaldi V, Donehower R, Leahy TL, Carr RA, Isaacson JD, Janus TJ, Andre A, Hosmane BS, and Padley RJ. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J. Clin. Oncol. April 15 2002, 20 (8):2171-2180.

  101. Walsh PC, DeWeese TL and Eisenberger MA. A Stuctured Debate: Immediate Versus Deferred Androgen Suppression In Prostate Cancer – Evidence for Deferred Treatment.The Journal of Urology Vol. 166, 508-516, August 2001.

  102. Egorin, M.J., Suhowski, E.G., Laufer, M., Trueheart, I., Haisfield-Wolf, M.E., Nativ, O., Eisenberger, M., Schoenberg, M.; University of Pittsburgh Cancer Institute, Pittsburgh, PA; The Johns Hopkins Hospital, Baltimore, MD; Bnai-Zion Medical Center, Haifa, Israel. Plasma pharmacokinetics and urinary recovery of intravesically administered gemcitabine. Proceedings of the American Society for Clinical Oncology, 21:90a (359), 2002

  103. Tangen, C., Crawford, E.D., Faulkner, J., Thompson, I., Eisenberger, M., Hussain, M., SWOG Statistical Center, Seattle, WA: University of Colorado Health Sciences Center, Denver, CO; University of Texas Health Sciences Center at San Antonio, San Antonio, TX, Johns Hopkins University, Baltimore, MD, Wayne State University, Detroit, MI. Ten-year survival in patients with metastatic (M+) prostate cancer (CaP): analysis of Southwest Oncology Group (SWOG) 8894. Proceedings of the American Society for Clinical Oncology, 21:188a (749), 2002.

  104. Sartor, A.O., Tangen, C., Hussain, M., Eisenberger, M., Crawford, E.D.; LSU Medical School, New Orleans, LA: SWOG, Seattle, WA; Wayne State University, Detroit, MI; Johns Hopkins, Baltimore, MD; University of Colorado, Denver, CO. Anti-androgen withdrawal in prostate cancer: results from SWOG 9426. Proceedings of the American Society for Clinical Oncology, 21:197a (785), 2002.

  105. Crawford D, Faulkner J, Thompson IM, Eisenberger MA, Tangen CM, Hussain MH. Ten-Year Survival In Patints with Metastatic (M=) Prostate Cancer (CAP): Analysis of Southwest Oncology Group (SWOG) 8894. AUA Program Abstracts, Vol 167 (4):304 (Abstr. 1202), 2002.

  106. Sinibaldi V, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, and Eisenberger MA. Phase II Evaluation of Docetaxel plus One-Day Oral Estramustine Phosphate in the Treatment of Patients with Androgen Independent Prostate Carcinoma. Cancer 2002 Mar 1;94(5):1457-65.

  107. Eisenberger MA. Therapeutic considerations for patients with high-risk, nonmetastatic, prostate cancer. Semin. Urol. Oncol. August 2002, Vol 20 (3 Suppl 1):19-23.

  108. Sinibaldi V, Carducci M, Denmeade S, Pili R, Zhurak M,Eisenberger MA; The Johns Hopkins University, Baltimore, MD. A randomized, double-blinded, phase I/II study of 3 doses of Marimastat in patients with hormone naïve, biologically relapsed (M0) prostate cancer (PCA). Proceedings of ASCO Vol 2:164b (Abstr. 2474), 2002.

  109. Lassiter LK and Eisenberger MA. The Dilemma of Patients with a Rising PSA Level After Definitive Local Therapy for Prostate Cancer. Seminars in Urologic Oncology, May 2002; Vol. 20, No. 2:146-154.

  110. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, and Walsh PC. Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy For Clinically Localized Prostate Cancer. J. of Urology, Vol. 169:517-523, February 2003.

  111. Eisenberger MA, Partin AW, Pound C, Roostelaar CV, Epstein J, Walsh P; Johns Hopkins University, Baltimore, Maryland. Natural history of progression of patients with biochemical (PSA) relapse following radical prostatectomy. Annual Meeting,ASCO, p.123 (Abstr 1527), 2003.

  112. Rosenbaum E, Sinibaldi V, Carducci MA, Zahurak M, Pili R, Denmeade S, Sokoll L, Epstein J, Partin A, Eisenberger MA; Johns Hopkins University, Baltimore, Maryland. Evidence of a dose/response relationship with marimastat in patients with biochemicaly relapsed prostate cancer (PCa). Proceedings of ASCO, p. 439 (Abstr. 1762), 2003.

  113. Sinibaldi V, Garrett E, Rosenbaum E, DeWeese T, Carducci MA, Pili R, Eisenberger MA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. The outcome of androgen suppressed prostate cancer (PCa) patients after biochemical (PSA) relapse and no clinical/radiological evidence of metastasis (MO). Proceedings of ASCO, p. 443 (Abstr. 1778), 2003.

  114. Partin AW, Humphreys EB, Mangold LA, Klicos N, Eisenberger MA, Walsh P, Baltimore, MD. Prostate Specific Antigen Doubling Time After Radical Prostatectomy As A Predictor of Cause Specific Survival .The Journal of Urology, AUA Annual Meeting, p. 382 (Abstr. 1451), 2004.

  115. Partin AW, Eisenberger MA, Sinibaldi V, Humphreys E, Mangold LA, Klicos N, Walsh P; Department of Urology and Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD. Prostate Specific Antigen Doubling Time (PSADT) Predicts For Distant failure And Prostate Cancer Specific Survival (PCSS) In Men With Biochemical Relapse After Radical Prostatectomy (RP), Annual ASCO Meeting, p. 394 (Abstr. 4555), 2004.

  116. Galsky MD, Eisenberger MA, Moore-Cooper S, Kelly WK, Slovin S, Morales A, Curley T, Delacruz A, Webb IJ, Scher HI; Memorial Sloan Kettering Cancer Center, New York, NY; Johns Hopkins Medical Institutions, Baltimore, MD; Millennium Pharmaceuticals, Cambridge, MA. Phase I trail of MLN2704 in patients with castrate-metastatic prostate cancer (CMPC). Annual ASCO Meeting p. 403 (Abstr. 4592), 2004.

  117. Rosenbaum E, Kibel A, Roth BJ, Wilding G, Dreicer R, Shatta B, Petrylak D, Dipaola RS, Beer TM, Eisenberger MA; The Sidney Kimmel Comprehensive Cancer Center Baltimore, MD; Washington University, School of Medicine, St. Louis, MO; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Wisconsin Comprehensive Cancer Center, Madison ,WI; Cleveland Clinic Foundation, Cleveland, OH; University of Pittsburgh, Pittsburgh, PA; Columbia-Presbyterian Medical Center, New York, NY; Cancer Institute of New Jersey (CINJ), New Brunswick, NJ; Oregon Health & Science University, Portland, OR. Adjuvant weekly Docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): Preliminary data of a multicenter pilot trial. Annual ASCO Meeting, p.417 (Abstract # 4649), 2004.

  118. Eisenberger MA, Dewit R, Tannock I et al . A comparison of Weekly or every 3 weeks Docetaxel vs Mitoxantrone + prednisone in patients with Hormone Refractory Prostate Cancer. Annual ASCO meeting (Abstract #4) –Plenary presentation, 2004.

  119. Rosenbaum E, Eisenberger MA. Survival Benefit for Hormone Refractory Prostate Cancer Patients Treated With Docetaxel: Commentary on tax 327. American Journal of Urology Review, December 2004.

  120. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Odard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 Oct 7;351(15):1502-12.

  121. G. K. Bajaj, E. Garrett-Mayer, R. Drew, V. J. Sinibaldi, M. Gaver, R. Pili, S. Denmeade, M. A. Carducci,Eisenberger MA, T. L. Deweese. A Phase II Study of Imatinib Mesylate In Prostate Cancer Patients With Evidence of Biochemical Relapse Following Definitive Radical Retropubic Prostatectomy or Radiation Therapy. 2005 Annual ASCO Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 3092

  122. G. K. Bajaj, E. Garrett-Mayer, R. Drew, V. J. Sinibaldi, M. Gaver, R. Pili, S. Denmeade, M. A. Carducci, Eisenberger MA, T. L. Deweese. A Phase II Study of Imatinib Mesylate In Prostate Cancer Patients With Evidence of Biochemical Relapse Following Definitive Radical Retropubic Prostatectomy or Radiation Therapy. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 3092.

  123. E. Rosenbaum, A. Kibel, B. Roth, G. Wilding, R. Dreicer, G. Chatta, D. Petrylak, R. S. Dipaula, T. M. Beer, Eisenberger MA. A pilot multicenter phase II study of adjuvant Docetaxel (D) for high risk prostate cancer (PC) patients (pts) after radical prostatectomy (RP): Preliminary data. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 4565.

  124. S. J. Freedland, E. B. Humphreys, L. A. Mangold, Eisenberger MA, P. C. Walsh, A. W. Partin. Predicting Prostate Cancer Specific Mortality Following Biochemical Recurrence after Radical Prostatectomy. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 4546

  125. Rosenbaum E, Zahurak M, Sinibaldi V, Carducci MA, Pili R, Laufer M, DeWeese TL, Eisenberger MA. Marimastat in the treatment of patients with biochenically relapsed prostate cancer: A prospective randomized, double blind, phase I/II trial. Clinical Cancer Research, Vol. 11(12); 4437-4443, 2005

  126. Bastian P, Palapattu G, Lin X, Yegnasubramanian S, Mangold L, Trock B, Eisenberger MA, Partin A, Nelson W. Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Pecific Antigen Recurrence Following Radical Prostatectomy. American Association for Cancer Research, Vol. 11(11); 4037-4043, 2005.

  127. M. Roessner, R. de Wit, I. F. Tannock, N. Yateman, S. Yao, A. Yver, Eisenberger MA, on behalf of the TAX 327 Investigators. Prostate-specific antigen (PSA) response as a surrogate endpoint for overall survival (OS): Analysis of the TAX 327 Study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancer. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 4554.

  128. S. F. Slovin, M. A. Carducci, K. W. Beekman, R. Pili, C. Eicher, W. K. Kelly, M. J. Morris, D. Shaffer, Eisenberger MA, H. I. Scher. The Men’s cycle plus docetaxel (Doc) in prostate cancer patients with rising PSAs in the non-castrate state. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 4564.

  129. M. D. Galsky, Eisenberger MA, S. Moore-Cooper, W. K. Kelly, S. Slovin, L. Owens, A. DeLaCruz, T. Curley, I. J. Webb, H. I. Scher. First in man study of the prostate specific membrane antigen targeted immunoconjugate, MLN2704, in patients with progressive castrate metastatic prostate cancer (PCMPC): Updated results. 2005 Prostate Cancer Symposium, No.266.

  130. K. W. Beekman, W. K. Kelly, M. A. Carducci, Eisenberger MA, S. F. Slovin, M. J. Morris, K. Konopelski, C. Eicher, H. I. Scher. Rapid hormonal cycling with docetaxel for patients with rising PSA after definitive local therapy for prostate cancer. 2005 Prostate Cancer Symposium, No. 145.

  131. Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, Parting AW, Sidransky D. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res. 2005 Dec 1;11(23):8321-5.

  132. D. R. Berthold, G. Pond, R. De Wit,Eisenberger MA, I. F. Tannock. Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 06: 4516.

  133. G. R. Pond, D. R. Berthold, R. Dewit, Eisenberger MA, I. F. Tannock. Quality of life (QOL) of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) following treatment with docetaxel or mitoxantrone in the TAX-327 study. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 4557.

  134. V. J. Sinibaldi, M. A. Carducci, K. Elza-Brown, E. Rosenbaum, S. Denmeade, R. Pili, J. Walczak, E. Garrett-Mayer, S. Moore-Cooper, M. A. Eisenberger. A phase II evaluation of imatinib mesylate (G) in stage M0 prostate cancer (PC) patients (pts) on hormonal therapy (HT) with evidence of biochemical relapse. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 14612.

  135. D. V. Makarov, B. J. Trock, E. B. Humphreys, L. A. Mangold, M. A. Carducci, A. W. Partin, Eisenberger MA, P. C. Walsh. Factors influencing prostate cancer specific mortality in patients receiving delayed androgen deprivation therapy for metastasis after biochemical recurrence following radical prostatectomy. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 4571.

  136. S. J. Freedland, E. B. Humphreys, L. A. Mangold, Eisenberger MA, D. J. George, A. W. Partin. Public health impact of PSA doubling time after radical prostatectomy on prostate cancer specific and overall survival. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 4568

  137. E. Rosenbaum, A. Kibel, M. Kattan, E. Sugar, E. Garrett Mayer, M. A. Eisenberger. Adjuvant weekly docetaxel (D) for high-risk prostate cancer (PC) patients (pts) following radical prostatectomy (RP). 2006 ASCO Annual Meeting, Prostate Cancer Symposium. No. 84.

  138. D. R. Berthold, G. Pond, R. de Wit,Eisenberger MA, I. F. Tannock. Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study. 2006 ASCO Annual Meeting, Prostate Cancer Symposium, No. 140.

  139. D. R. Berthold, G. Pond, R. de Wit, M. A. Eisenberger, I. F. Tannock. Quality of life (QOL) of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) f ollowing treatment with docetaxel or mitoxantrone in the TAX-327 study.2006 ASCO Annual Meeting, Prostate Cancer Symposium. No. 214.

  140. D. Rathkopf, M. A. Carducci, S. Slovin, M. Morris, D. Shaffer, C. Eicher, M. Kelsen, Eisenberger MA, S. D. Baker, H. I. Scher. A phase II trial of docetaxel (Doc) with rapid hormonal cycling for patients with non-castrate metastatic prostate cancer. 2006 ASCO Annual Meeting, Prostate Cancer Symposium. No. 207.


AUDIOVISUAL

  • "Prostate Cancer" - Educational Section - Annual Meeting of the American Society of Clinical Oncology, Los Angeles, 1986 (Cassettes)

  • "Prostate Cancer" - Educational Section - American Society of Clinical Oncology, Orlando, Florida, 1993

  • A Prostate Cancer@ - Educational Section - American Society of Clinical Oncology, Atlanta, GA, 1999

  • CME Instruction - See Significant Participation In National or International Meetings
    Lectures/Symposia) - Including CME Instruction.

© Copyright 2013 | All Rights Reserved | Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287